Monitor the Pulmatrix special stockholders' meeting on October 16, 2026, for approval of the merger proposals. The key condition to watch is whether Eos secures the required $13 million in gross cash proceeds from financing transactions prior to closing. The combined company's post-merger trading symbol will be MTXL.
Price Chart
Executive Summary
Pulmatrix, Inc. filed Amendment No. 3 to its S-4 registration statement, detailing the proposed reverse merger with Eos SENOLYTIX, Inc. Under the merger agreement, Eos will become a wholly-owned subsidiary of Pulmatrix, and existing Pulmatrix securityholders are expected to own approximately 6% of the combined company on a fully-diluted basis, with Eos securityholders owning the remaining 94%. The filing includes financial statements, risk factors, and proposals for stockholder approval, including a reverse stock split and an increase in authorized shares, with a special meeting scheduled for October 16, 2026.
Key Facts
- Pulmatrix and Eos entered into a merger agreement on March 26, 2026, with Merger Sub merging into Eos, leaving Eos as a wholly-owned subsidiary.
- Existing Pulmatrix securityholders are expected to own approximately 6% of the combined company on a fully-diluted basis, excluding CEO RSUs.
- Eos securityholders are expected to own approximately 94% of the combined company.
- The estimated exchange ratio is approximately 8.55 shares of Pulmatrix common stock for each share of Eos capital stock.
- The combined company will be renamed Eos SENOLYTIX Inc. and is expected to trade on Nasdaq under the symbol MTXL.
- Pulmatrix reported a net loss of $5.2 million for the year ended December 31, 2025, and had an accumulated deficit of $302.3 million as of that date.
- As of June 30, 2026, Pulmatrix had approximately $2.2 million in cash and cash equivalents.
- The merger is subject to stockholder approval of several proposals, including the issuance of shares representing more than 20% of outstanding stock, a reverse stock split, and an increase in authorized shares.
- A condition to closing requires Eos to have received at least $13 million in gross cash proceeds from financing transactions.
- SENOTHERAPEUTIX, Inc. is expected to beneficially own more than 50% of the voting power of the combined company, making it a controlled company.
- Pulmatrix's lead product candidates include PUR3100 (acute migraine), PUR1800 (COPD), and PUR1900 (ABPA), all in clinical development.
- Eos's lead product candidate, PTC-2105, is a preclinical-stage MitoXcel geropeptide for sarcopenia and sarcopenic obesity.
- Pulmatrix has retained Gemini Valuation Services, LLC to provide a fairness opinion on the exchange ratio.
- Pulmatrix has entered into a retention bonus agreement with its Interim CEO, Peter Ludlum, for up to $75,000 in total bonuses tied to the S-4 filing acceptance and the special stockholders' meeting.
Financial Impact
Pulmatrix's existing stockholders will be diluted to approximately 6% ownership of the combined entity. The implied value of Pulmatrix's 6% equity interest is approximately $7.85 million based on a $100 million pre-money valuation for Eos plus $18 million in anticipated capital and $1 million in Series B Preferred investment.
Risk Factors
- The merger may not close if stockholder approvals are not obtained or if Eos fails to secure the required $13 million in financing.
- Existing Pulmatrix stockholders face substantial dilution, retaining only ~6% ownership of the combined company.
- The combined company will be a controlled company, with SENOTHERAPEUTIX, Inc. holding more than 50% voting power, reducing minority stockholder protections.
- Pulmatrix has a history of net losses and may need additional capital post-merger to fund operations.
- Eos's product candidates are in early preclinical stages and may never receive regulatory approval or be commercialized.
Investment Themes
Documents Analyzed
This report is based on 12 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001493152-26-043145 |
| Exhibit: ex10-38.htm | 0001493152-26-043145 |
| Exhibit: ex10-35.htm | 0001493152-26-043145 |
| Exhibit: ex10-36.htm | 0001493152-26-043145 |
| Exhibit: ex10-37.htm | 0001493152-26-043145 |
| Exhibit: ex99-7.htm | 0001493152-26-043145 |
| Exhibit: ex23-1.htm | 0001493152-26-043145 |
| Exhibit: ex23-3.htm | 0001493152-26-043145 |
| Exhibit: ex23-2.htm | 0001493152-26-043145 |
| Document: 0001493152-26-043145-index-headers.html | 0001493152-26-043145 |
| Document: 0001493152-26-043145-index.html | 0001493152-26-043145 |
| Document: 0001493152-26-043145.txt | 0001493152-26-043145 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 5d ago | EFFECT | $1.48 | awaiting T+5 | — | $1.49 (−0.68%) |
Oct 22, 2026 5d ago | 425 | $1.42 | awaiting T+5 | — | $1.49 (+4.93%) |
Oct 13, 2026 14d ago | 425 | $1.38 $1.43 | ▲ +3.62% | ▲ +4.77% | $1.49 (+7.97%) |
Oct 7, 2026 20d ago | DEFA14A | $1.53 $1.41 | ▼ −7.67% | ▼ −7.39% | $1.49 (−2.43%) |
Oct 2, 2026 25d ago | S-3/A | $1.48 $1.43 | ▲ +3.38% | ▲ +3.80% | $1.49 (−0.68%) |
Sep 28, 2026 4w ago | EFFECT | $1.59 $1.48 | ▲ +6.92% | ▲ +8.12% | $1.49 (+6.29%) |
Sep 25, 2026 4w ago | DEFM14A | $1.59 $1.48 | ▲ +6.92% | ▲ +8.12% | $1.49 (+6.29%) |
Sep 23, 2026 4w ago | S-4/A | $1.67 $1.54 | ▼ −7.78% | ▼ −7.37% | $1.49 (−10.78%) |
Sep 22, 2026 5w ago | 425 | $1.69 $1.52 | ▼ −9.79% | ▼ −9.12% | $1.49 (−11.57%) |
Sep 17, 2026 5w ago | S-4/A | $1.44 $1.61 | ▲ +11.81% | ▲ +10.54% | $1.49 (+3.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers